MRF Breakthrough Consortium Leaders & MRF-Supported Researchers Named AACR Fellows

The American Association of Cancer Research (AACR) recently named a current and former member of the MRF Breakthrough Consortium as Fellows in the AACR Academy. MRF-supported researchers Keith Flaherty, MD and Jedd Wolchok, MD, PhD were recognized as distinguished leaders whose scientific contributions have advanced significant innovation and progress in cancer research.

Dr. Flaherty was recognized for his groundbreaking translational discoveries advancing therapeutic agents, and Dr. Wolchok was honored for his many impactful contributions to novel cancer immunotherapy strategies. “Keith is essentially the leader in targeted therapies for cancer; Jedd is the leader in immunotherapies for cancer,” said Michael B. Atkins, MD, Co-Chair of the MRF’s Scientific Advisory Committee. “They have had tremendous impact, not just in melanoma, but in the treatment of all cancers.”

We are grateful to Dr. Flaherty and Dr. Wolchok, and all the members of our Scientific Leadership team, for guiding our work and leading the field towards more effective treatments in melanoma, many of which also benefit the broader cancer community. Please join us in congratulating these members of the MRF community for this well-deserved honor!

More information about the AACR Academy and new class of Fellows can be found on the AACR website.